amerisourcebergen corp (ABC) Details
AmerisourceBergen Corporation, a pharmaceutical services company, provides drug distribution and related healthcare services and solutions to pharmacy, physician, and manufacturer customers primarily in the United States and Canada. The company distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also offers pharmacy automation, inventory management, reimbursement and pharmaceutical consulting, staffing, logistics, and pharmacy management services to healthcare providers and pharmaceutical manufacturers. In addition, the company provides scalable automated pharmacy dispensing equipment, medication and supply dispensing cabinets, and supply management software to various retail and institutional healthcare providers. Further, it offers pharmaceutical distribution and other services to physicians, who specialize in various disease states; distributes plasma and other blood products, injectible pharmaceuticals, and vaccines; and provides third party logistics, reimbursement support programs, outcomes research, contract field staffing, patient and copay assistance, adherence programs, risk mitigation, and other market access programs and services to pharmaceutical and biotechnology manufacturers. Additionally, the company delivers packaging solutions to institutional and retail healthcare providers. It operates through a network of distribution service centers and other operations. AmerisourceBergen Corporation was founded in 1985 and is headquartered in Chesterbrook, Pennsylvania.
Last Reported Date: 11/27/12
Founded in 1985
amerisourcebergen corp (ABC) Top Compensated Officers
Chief Executive Officer, President, Director ...
Total Annual Compensation: $1.1M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $363.2K
Senior Vice President and President of Ameris...
Total Annual Compensation: $538.5K
Senior Vice President and President of Global...
Total Annual Compensation: $391.8K
Senior Vice President and President of Ameris...
Total Annual Compensation: $375.4K
Compensation as of Fiscal Year 2012.
AmerisourceBergen Corporation Elects Lon R. Greenberg to its Board of Directors
May 16 13
AmerisourceBergen Corporation announced that Lon R. Greenberg has been elected to its Board of Directors, effective immediately. Mr. Greenberg fills the vacancy created by Charles H. Cotros's retirement from the Board in February 2013. Mr. Greenberg also joined the Audit and Corporate Responsibility Committee and Finance Committee of the Board. Mr. Greenberg served as the Chief Executive Officer of UGI Corporation from 1995 until his retirement on April 1, 2013. Mr. Greenberg continues to serve as the Chairman of UGI's Board of Directors, a position he has held since 1996. In addition to serving as the Chairman of the Board of UGI Corporation, Mr. Greenberg is a director of Aqua America Inc. and Ameriprise Financial Inc. Mr. Greenberg also is a member of the Board of Trustees of Temple University, the Board of Directors of Temple University Health System, and the Board of Directors of Fox Chase Cancer Center. Furthermore, he currently serves as Chair of the Board of Directors of the United Way of Greater Philadelphia and Southern New Jersey.
AmerisourceBergen Corporation Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended March 31, 2013; Reaffirms Earnings Guidance for the Fiscal Year 2013
Apr 25 13
AmerisourceBergen Corporation announced unaudited consolidated earnings results for the second quarter and six months ended March 31, 2013. For the quarter, the company reported revenue of $20,523,668,000 in the second quarter of fiscal 2013, a 4.1% increase over $19,708,371,000 for the same quarter in the previous fiscal year, driven by a 3.9% increase in the company AmerisourceBergen Drug Corporation (ABDC) revenue, a 3.9% increase in AmerisourceBergen Specialty Group (ABSG) revenue, and a 46.9% increase in the manufacturer services businesses, reported in other. Operating income decreased 7.1% to $350,123,000 compared to $353,816,000 a year ago, due to the increase in operating expenses which was offset in part by the increase in gross profit. Income from continuing operations before income taxes was $330,864,000 against $353,816,000 a year ago. Income from continuing operations was $204,143,000 against $219,143,000 a year ago. Net income was $45,634,000 or $0.19 per diluted share against $212,105,000 or $0.03 per diluted share a year ago. Diluted earnings per share from continuing operations were up 3.6% to $0.87 in the second quarter of fiscal 2013 compared to $0.84 in the previous fiscal year's second quarter. Diluted earnings per share growth were driven by the 10.6% reduction in diluted average shares outstanding. The company generated about $950 million of free cash flow. Cash flow from operations were $985.4 million.
For the six months, the company reported revenue of $41,583,479,000 against $39,689,556,000 a year ago. Operating income was $649,563,000 against $660,463,000 a year ago. Income from continuing operations before income taxes was $611,802,000 against $614,934,000 a year ago. Income from continuing operations was $378,764,000 or $1.61 per diluted share against $380,735,000 or $1.45 per diluted share a year ago. Net income was $214,245,000 or $0.91 per diluted share against $374,221,000 or $1.42 per diluted share a year ago. Net cash provided by operating activities from continuing operations was $698,224,000 against $742,377,000 a year ago. Net cash provided by operating activities was $743,655,000 against $668,124,000 a year ago. Capital expenditures were $88,377,000 against $63,481,000 a year ago. For the six months the company now stands at approximately $655 million of free cash flow, about the same level as last year. Some of the free cash flow benefit was a result of timing.
The company reaffirmed its earnings guidance for the fiscal year 2013. For the year, the company’s adjusted diluted earnings per share from continuing operations in the range of $3.04 to $3.14, though likely in the lower half of the range. The company expects adjusted diluted earnings per share from continuing operations in fiscal year 2013 to be in the lower half of the range of $3.04 to $3.14, excluding certain expenses related to the company's new strategic long-term relationship with Walgreens and Alliance Boots, including the warrants issued, and the expected LIFO charge from on boarding of additional branded inventory. Excluding the two items mentioned, the company now expects revenue growth in the 11% to 13% range; operating income decline in the 3% to 5% range; an operating margin decline in the range of 24 to 29 basis points; and free cash flow in the range of $100 million to $200 million, which includes capital expenditures of at least $220 million. The company announced that as a result of the pending sale of AmerisourceBergen Canada Corporation and the classifying of its operating results as discontinued operations, the company will retroactively adjust its financial results for fiscal year 2012. Total consolidated revenues for the company in fiscal 2012 will be adjusted to $78.1 billion, consolidated operating income will be adjusted to $1.3 billion, and GAAP diluted earnings per share from continuing operations will be adjusted to $2.96. For the full fiscal year, the company expects its tax rate to be in the range of about 38.2% for continuing operations.